Meanwhile, other pharma companies are also developing checkpoint inhibitors for adjuvant RCC, including Roche ... which is testing its Imfinzi (durvalumab) alone and in combination with CTLA4 ...

Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...

ALTHOUGH UPDATED OVERALL survival (OS) findings from KEYNOTE-564 (NCT03142334) demonstrated continued benefit in patients with clear cell renal cell carcinoma (ccRCC) who received adjuvant ...

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.

In the phase 3 NIAGARA trial (NCT03732677), the combination of neoadjuvant durvalumab (Imfinzi) plus chemotherapy, followed by adjuvant durvalumab, led to significantly improved ... Belzutifan ...

In the Durvalumab arm, patients were randomized to receive Durvalumab with Gemcitabine + Cisplatin (GC) for 4 cycles, followed by RC and adjuvant Durvalumab for up to 8 cycles. In the comparator arm, ...

The median progression-free survival was 15.0 months with TACE plus durvalumab and bevacizumab and 8.2 months with TACE alone. Durvalumab plus bevacizumab and transarterial chemoembolization (TACE ...

“Our findings suggest that durvalumab did not improve outcomes compared with cetuximab in patients with HNSCC with contraindications to cisplatin,” the authors concluded. “These findings are ...